BPC-157
A synthetic peptide with intriguing animal healing data but essentially no quality human trials; it is a research chemical, not an approved or legal consumer product.
Overview
BPC-157, sometimes called Body Protection Compound 157, is a synthetic peptide consisting of a short chain of amino acids. Its sequence is described as being derived from a protein found in human gastric juice. It has attracted substantial attention online and in some athletic and biohacking circles for claims related to healing of tendons, muscle, gut tissue, and other structures.
Emerging evidenceIt is important to be direct at the outset. BPC-157 is not an approved medicine and is not a legal dietary supplement. It is sold only as a research chemical, is not manufactured to pharmaceutical quality standards, and is prohibited in sport. The scientific evidence behind it is almost entirely preclinical, drawn from rodents and laboratory cultures, with essentially no rigorous human trials. This profile exists to explain what is and is not known, and it does not recommend that anyone obtain or use BPC-157 or any other compound.
How it works
The proposed mechanisms for BPC-157 come almost entirely from animal and cell studies, and they should be read as hypotheses rather than established facts in humans.
The most frequently discussed mechanism is angiogenesis, the formation of new blood vessels. In animal models, the peptide has been reported to promote blood vessel growth around injured tissue, which could in principle support healing by improving oxygen and nutrient delivery. Related work points to interactions with growth factor pathways and with the nitric oxide system, which is involved in blood flow and tissue protection.
Other proposed actions include effects on fibroblasts, the cells that produce collagen and help rebuild connective tissue, and modulation of certain growth factor receptors involved in tendon and ligament repair. Some researchers have also described effects on the gut lining and on the interaction between the brain and the digestive system in animals.
The critical caveat is that these mechanisms are inferred from controlled laboratory conditions in animals, often at doses and delivery methods that do not translate simply to humans. How, or whether, any of this occurs in the human body is not established.
What the research shows
The preclinical literature is genuinely interesting, which is part of why the compound generates so much attention. In rodent studies, BPC-157 has been reported to speed healing of tendon, muscle, ligament, and bone injuries, to protect and heal the gastrointestinal tract in models of ulcers and inflammatory damage, and to show protective effects in various other tissues. A number of these studies come from a single research group that has published extensively on the compound over many years.
Cell culture work has similarly reported favorable effects on tendon fibroblast survival, migration, and function, supporting the idea that the peptide could influence connective tissue repair.
The decisive limitation is the near-total absence of human evidence. There are no published, adequately powered, placebo-controlled clinical trials demonstrating that BPC-157 is safe or effective in people for tendon injury, gut conditions, or anything else. Claims of human benefit rest on animal extrapolation and anecdote, not controlled data. Because there are no such trials, no meaningful human dosing has been established, and any figures circulated online are not grounded in clinical research. This profile deliberately presents no dosing.
Evidence quality
By any rigorous standard, the human evidence for BPC-157 is insufficient, and the overall body of work is best described as emerging. The animal literature, while sometimes striking, has notable weaknesses. A large share of the positive studies originate from one closely associated group of researchers, which limits independent replication. Many studies use small samples, varied injury models, and routes of administration that may not reflect real-world use.
Crucially, animal healing results have a poor track record of translating directly to humans across pharmacology in general, so encouraging rodent data cannot be assumed to predict human outcomes. The gap between preclinical promise and proven human benefit is exactly where many candidate compounds fail.
Layered on top of the scientific uncertainty are quality and safety concerns specific to research chemicals. Because BPC-157 is not produced under pharmaceutical manufacturing controls, products sold under its name can vary in purity, concentration, and contamination. The combination of unknown human efficacy, unknown human safety, and uncertain product quality is why this compound cannot be treated as a validated intervention.
Open questions
Almost everything about BPC-157 in humans is an open question. Whether it produces any of its animal-observed effects in people, whether it is safe over any duration, how it is absorbed and distributed, and whether specific injuries or conditions might respond are all unresolved. The field lacks the controlled human trials that would be required to answer these questions.
Until independent, well-designed human research exists, BPC-157 should be understood as an experimental research chemical whose reputation currently rests on preclinical findings and anecdote rather than established human evidence.
Because BPC-157 is not a legal or approved consumer product, this profile includes no product information, no sourcing, and no recommendation of any kind. Nothing here should be read as guidance to obtain or use it. Questions about injury, recovery, or any medical condition belong with a qualified healthcare professional.
Referenced research
- A review by the peptide's primary research group summarized animal studies suggesting effects on gut and tissue healing. Sikiric et al., Current Pharmaceutical Design, 2010
- In a rat model, the peptide was reported to accelerate tendon-to-bone healing and improve tendon fibroblast function in culture. Chang et al., Journal of Applied Physiology, 2011
- A narrative review catalogued preclinical reports of angiogenic and tissue-protective effects, while noting the near-total absence of human data. Gwyer et al., Cell and Tissue Research, 2019
- A review described proposed mechanisms in animal models but did not present controlled human efficacy trials. Seiwerth et al., a 2018 review in Current Pharmaceutical Design
Frequently asked
Is BPC-157 approved or legal to use?
No. BPC-157 is not an approved drug in the United States, the European Union, or other major jurisdictions, and it is not a legal dietary supplement. It is sold only as a research chemical and is prohibited in sport by the World Anti-Doping Agency. It should not be treated as a consumer product.
Does it work in humans?
This is genuinely unknown. Nearly all evidence comes from rodents and cell cultures. There are no published, high-quality, placebo-controlled human trials establishing that BPC-157 is safe or effective for any condition.
Where does the peptide come from?
BPC-157 is a synthetic sequence described as derived from a protein found in gastric juice. It does not exist as this specific isolated peptide in nature, and it is a laboratory-made compound.
Are there safety concerns?
Because human data are essentially absent, its safety profile in people is unknown. Purity and contamination of research-chemical products are additional documented concerns, since such products are not manufactured to pharmaceutical standards.